However, according to data from 2024, more than half of people living with MS are 50 years of age 1
[10] [11] People with severe gastrointestinal disease, including severe gastroparesis, should consult their healthcare provider before using fibre supplements, as GLP-1 medications are generally not recommended in these conditions
As this trend evolves, staying informed will help patients navigate GLP-1 treatment safely and confidently. GLP-1 Lawsuits In addition to patients microdosing, thousands who have already been affected by side effects linked to Ozempic, Wegovy and Mounjaro use are currently pursuing GLP-1 lawsuits in federal courts nationwide
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2